31 registrations that name triptorelin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 31 registrations
Status
Phase
887US sites across 51 states
1
2 to 4
5 to 19
20 or more
All 31 registrations
RecruitingNCT04423211
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Phase 3
ECOG-ACRIN Cancer Research Group
About 804 people
Started Oct 8, 2020
In plain words A Phase 3 study of triptorelin in male participants 18 and older, run by ECOG-ACRIN Cancer Research Group. It plans to enroll about 804 people at 341 US sites.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Biochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8.
STEP 0: REGISTRATION ELIGIBILITY CRITERIA
Patient must be male and >= 18 years of age.
Patient must have had a radical prostatectomy (RP) as definitive therapy for histopathologically-proven prostatic adenocarcinoma
Patient must have biochemical recurrence (BCR) after RP, defined as follows:
32 more inclusion criteria and the exclusion criteria are on the listing.
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). The full summary is on the listing.
Where, as registered
341 US sites in 34 states.
RecruitingNCT03678025
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Phase 3
SWOG Cancer Research Network
About 1,273 people
Started Sep 24, 2018
In plain words A Phase 3 study of triptorelin in male participants 18 and older, run by SWOG Cancer Research Network. It plans to enroll about 1,273 people at 338 sites, 334 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8.
STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: All patients must have a histologically or cytologically proven diagnosis of adenocarcinoma of the prostate.
STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients must have an intact prostate. No prior local therapy for prostate adenocarcinoma is allowed (e.g., brachytherapy, high-intensity focused ultrasound \[HIFU\], cryotherapy, laser…
STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients must have evidence of metastatic disease on technetium bone scan and computed tomography (CT) or magnetic resonance imaging (MRI) within 42 days prior to starting standard systemic…
STEP 1 REGISTRATION: DISEASE-RELATED CRITERIA: Patients with known brain metastases are not eligible. Brain imaging studies are not required for eligibility if the patient has no neurologic signs or symptoms suggestive of brain metastasis.
20 more inclusion criteria and the exclusion criteria are on the listing.
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Where, as registered
334 US sites in 43 states; also Chile (1), Colombia (1), Mexico (1), Switzerland (1).
RecruitingNCT06513962
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Phase 3
Children's Oncology Group
About 60 people
Started Feb 27, 2025
In plain words A Phase 3 study of triptorelin in female participants up to 39, run by Children's Oncology Group. It plans to enroll about 60 people at 206 sites, 201 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants up to 39. Conditions: Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm.
< 40 years of age at the time of enrollment
Patient must be a post-menarchal female and report that their initial menstrual period occurred > 6 months prior to enrollment. (Current menstrual status is not part of the inclusion criteria.)
Newly diagnosed with first cancer, exclusive of breast cancer.
Note: Apart from breast carcinoma, other tumor types originating in the breast are permitted (e.g., sarcoma, lymphoma).
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Best Practice; Biospecimen Collection; Electronic Health Record Review; Survey Administration; Triptorelin Pamoate
Registered summary
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The full summary is on the listing.
Where, as registered
201 US sites in 41 states; also Canada (5).
RecruitingNCT01492972
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Phase 3
Proton Collaborative Group
About 192 people
Started Jan 2012
In plain words A Phase 3 study of triptorelin in male participants 18 and older, run by Proton Collaborative Group. It plans to enroll about 192 people at 4 US sites.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Prostate Cancer.
Histologically confirmed prostate adenocarcinoma (within 365 days of randomization) at intermediate risk for reoccurrence determined by at least one of the following: Gleason Score 7, PSA > = 10 and < = 20, T stage T2b - T2c
Clinical stages T1-T2c N0 M0 as staged by the treating investigator. (AJCC Criteria 7th Ed.- appendix III).
Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason score must be in the range of 2-7. > 6 cores are strongly recommended.
PSA values < = 20 ng/ml within 90 days prior to randomization. Obtained prior to biopsy or at least 21 days after prostate biopsy.
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Radiation; Androgen Suppression Therapy
Registered summary
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not completely understood. This study will compare the use of hypofraction proton therapy (28 treatments) alone to proton therapy with androgen suppression therapy.
Where, as registered
4 US sites in 4 states.
RecruitingNCT06378866
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Phase 2
Mayo Clinic
About 532 people
Started Jun 3, 2024
In plain words A Phase 2 study of triptorelin in male participants 18 and older, run by Mayo Clinic. It plans to enroll about 532 people at 3 US sites.
This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in treating patients with hormone sensitive prostate cancer that has spread from where it first started to other places in the body (metastatic), and that has come back after a period of improvement (recurrent). It also studies the effects of salvage radiation therapy (sXRT) on prostate cancer and to see if radiation to the pelvis helps prevent prostate cancer from spreading elsewhere. The full summary is on the listing.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
About 60 people
Started Mar 9, 2026
In plain words A Phase 2 study of triptorelin in male participants 18 and older, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Metastatic Castration-resistant Prostate Cancer.
Age ≥ 18 years
Performance status ≤2.
Documented histologically confirmed adenocarcinoma of the prostate.
Baseline PSA ≥1.0 ng/ml.
16 more inclusion criteria and the exclusion criteria are on the listing.
The objective of this study is to determine the safety and clinical effects of alternating pharmacologic (i.e. supraphysiologic) testosterone therapy with darolutamide in men with metastatic prostate cancer as first line hormonal therapy. Correlative studies will be conducted to assess the effect of alternating therapy on quality of life, gene expression and metabolic changes associated with alternating therapy.
Where, as registered
1 US site in 1 state.
RecruitingNCT06059118
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
About 50 people
Started Oct 4, 2023
In plain words A Phase 2 study of triptorelin in male participants 18 and older, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. It plans to enroll about 50 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Prostate Cancer.
Eastern Cooperative Oncology Group (ECOG) Performance status ≤2.
Age ≥18 years.
Histologically-confirmed adenocarcinoma of the prostate.
Treated with continuous androgen ablative therapy (either surgical castration or LHRH agonist/antagonist).
26 more inclusion criteria and the exclusion criteria are on the listing.
Asymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC) without pain due to prostate cancer will be treated on an open label study to evaluate effectiveness of sequential treatment with the combination of difluoromethylornithine (DFMO) and high dose testosterone in sequence with enzalutamide to improve primary and secondary outcomes.
Where, as registered
1 US site in 1 state.
RecruitingNCT06922318
The COSMYC Trial (COmbined Suppression of MYC)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
About 50 people
Started Aug 19, 2025
In plain words A Phase 2 study of triptorelin in male participants 18 and older, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. It plans to enroll about 50 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Metastatic Castration-resistant Prostate Cancer.
Eastern Cooperative Oncology Group (ECOG) Performance status ≤2.
Age ≥18 years.
Histologically-confirmed adenocarcinoma of the prostate.
Treated with continuous androgen ablative therapy (either surgical castration or LHRH agonist/antagonist).
21 more inclusion criteria and the exclusion criteria are on the listing.
This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigators also want to determine if dosing first with the combination of testosterone and ZEN-3694 may cause enzalutamide and ZEN-3694 to work more effectively.
Where, as registered
1 US site in 1 state.
RecruitingNCT07455903
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Phase 2
Baptist Health South Florida
About 50 people
Started Jul 29, 2026
In plain words A Phase 2 study of triptorelin in male participants 18 and older, run by Baptist Health South Florida. It plans to enroll about 50 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Prostate Cancer; Localized Prostate Carcinoma.
Signed informed consent must be obtained prior to participation in the study.
Males aged ≥18 years.
ECOG performance status ≤ 1
Histologically confirmed adenocarcinoma of the prostate in a patient amenable to radical prostatectomy
10 more inclusion criteria and the exclusion criteria are on the listing.
The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT. Follow up will be 48 months your prostate removal to do a blood test and log if any new or worsening symptoms have occurred as a part of your standard-of-care (SOC).
Where, as registered
1 US site in 1 state.
RecruitingNCT06473259
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
Observational
Santa Chiara Hospital
About 3,000 people
Started Dec 16, 2016
In plain words An observational study of triptorelin in male participants of any age, run by Santa Chiara Hospital. It plans to enroll about 3,000 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants of any age. Conditions: Prostate Cancer; Hormone Sensitive Prostate Cancer; Metastatic Tumor.
histologically confirmed diagnosis of adenocarcinoma of the prostate, metastatic, not undergoing previous treatment (except hormone therapy initiated no more than 4-6 months prior to docetaxel) for metastatic disease
treatment with docetaxel, ARPI (alone or in combination) or with radiation therapy on the primary tumor in combination with ADT within normal clinical practice or expanded access programs initiated between January 2015 and December 2027.
availability of inpatient and/or outpatient medical records for clinical data collection
The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice
Where, as registered
No US site; Italy (3).
RecruitingNCT07751133
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
Phase 3
University College, London
About 1,500 people
Started Aug 28, 2026
In plain words A Phase 3 study of triptorelin in male participants 18 and older, run by University College, London. It plans to enroll about 1,500 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Prostate Cancer; mHSPC; mCRPC.
Adult males (male sex at birth) aged 18 years or older
Newly histologically or cytologically diagnosed prostate cancer (adenocarcinoma) that is metastatic hormone-sensitive (mHSPC) or metastatic castration resistant prostate cancer (mCRPC), for whom ARPI in combination with androgen…
Prior ADT use for prostate cancer (including bilateral orchidectomy and transcutaneous oestrogen), is permitted provided: (a) ADT has been started less than 12 weeks prior to randomisation in mHSPC, (b) In the adjuvant setting the…
ECOG performance status 0-2
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy
Registered summary
The goal of this phase 3 clinical trial is to determine the clinical effectiveness and cost effectiveness of using lower doses of Androgen Receptor Pathway Inhibitors (ARPI) to treat patients with prostate cancer that has spread (metastasized). The main questions it aims to answer are: 1. if overall survival for reduced dose ARPI is not worse than standard dose ARPI when treating patients with metastatic prostate cancer, and 2. that fatigue (extreme exhaustion) and not stopping ARPI permanently (due to adverse effects) are better than average with the reduced dose. The full summary is on the listing.
Where, as registered
No US site; United Kingdom (2).
RecruitingNCT04064840
GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET
Phase 3
The University of Hong Kong
About 784 people
Started Sep 1, 2019
In plain words A Phase 3 study of triptorelin in female participants 18 to 42, run by The University of Hong Kong. It plans to enroll about 784 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 42. Conditions: Subfertility.
What it tests, as registered
IVF: Decapeptyl and hCG; FET: Decapeptyl; IVF: hCG and normal saline; FET: Normal Saline
Registered summary
The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.
Where, as registered
No US site; China (1).
RecruitingNCT06150703
Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles
Phase 3
Assistance Publique - Hôpitaux de Paris
About 652 people
Started Jun 27, 2024
In plain words A Phase 3 study of triptorelin in female participants 18 to 39, run by Assistance Publique - Hôpitaux de Paris. It plans to enroll about 652 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 39. Conditions: In Vitro Fertilization; ICSI Intracytoplasmic Spermatozoid Injection.
Patients requiring conventional IVF or IVF with sperm injection (ICSI) from the partner or donor under the conditions of management defined by French law.
Patients aged 18 to 39 included
First or second attempt at IVF or ICSI for pregnancy
BMI < 35 kg/m2
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Ovulation induction with hCG + Luteal phase support with vaginal progesterone; Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin
Registered summary
The development of stimulation protocols for in vitro fertilisation (IVF) has led to a paradox. It has now been established that obtaining a large number of oocytes is a key to success, but that it is also a risk factor for embryo transfer failure after puncture (disruption of endometrial receptivity due to luteal insufficiency) and a risk factor for complications such as ovarian hyperstimulation syndrome (OHSS).
Where, as registered
No US site; France (1).
RecruitingNCT07128394
Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment
No phase
Nanjing University
About 590 people
Started Feb 1, 2024
In plain words A study of triptorelin in female participants 20 to 37, run by Nanjing University. It plans to enroll about 590 people at 1 site, none in the US.
Women aged 20 to 37 years (inclusive). Diagnosed with infertility and undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment using the long-acting GnRH agonist protocol.
This randomized controlled trial aims to evaluate whether supplementation with exogenous luteinizing hormone (LH) can improve embryo quality in patients undergoing in vitro fertilization (IVF) with a long gonadotropin-releasing hormone agonist (GnRH-a) protocol who have excessive suppression of LH. Eligible participants will be randomly assigned to receive either exogenous LH supplementation or standard care. The primary outcome is embryo quality, and secondary outcomes include pregnancy rates and safety assessments. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT05781217
Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
Phase 3
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
About 534 people
Started Mar 14, 2023
In plain words A Phase 3 study of triptorelin in people 18 and older, run by Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic. It plans to enroll about 534 people at 17 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Prostate Cancer; Salvage Radiotherapy; Biochemical Recurrence; Androgen Deprivation Therapy; Metastases-free Survival.
Patients with histologically-confirmed prostate cancer treated with radical prostatectomy. Patients who have not undergone lymph node dissection are eligible for inclusion.
Biochemical recurrence after prostatectomy: BCR is defined as a PSA value ≥ 0.2 ng/mL, with at least one confirmatory PSA determination ≥ two weeks after the first test (the confirmatory PSA level must be higher than the initial value).
Intermediate and high-risk patients according to the classification criteria proposed by González San Segundo et al. (18):
Testosterone level > 150 ng/dL at inclusion
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
triptorelin, goserelin, leuprorelin
Registered summary
The optimal indication for ADT has long been a point of controversy, at least until the results of randomised trials comparing RT with and without ADT were published. NCCN guidelines and most retrospective series and left the decision to prescribe ADT in combination with RT to the discretion of the treating physician, despite a lack of clear scientific evidence to support this recommendation. The full summary is on the listing.
Where, as registered
No US site; Spain (17).
RecruitingNCT05328258
Use of GnRHa During Chemotherapy for Fertility Protection
Phase 3
Kenny Rodriguez-Wallberg
About 500 people
Started Mar 31, 2023
In plain words A Phase 3 study of triptorelin in female participants 14 to 42, run by Kenny Rodriguez-Wallberg. It plans to enroll about 500 people at 17 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 14 to 42. Conditions: Breast Cancer Female; Acute Leukemia; Lymphoma; Osteosarcoma; Soft Tissue Sarcoma; Ewing Sarcoma.
Signed informed consent
Breast cancer or acute leukemias, lymphomas (Hodgkin and non-Hodgkin) or sarcomas (osteo, soft tissue and Ewing) confirmed by histology and assigned for diseace-specific chemotheraphy
Confirmed menarche
ECOG performance status 0-1
1 more inclusion criterion and the exclusion criteria are on the listing.
Many cytotoxic drugs may harm the fertility of young women treated for cancer. The aim of the study is to investigate if the Gonadotropin-Releasing Hormone agonist (GnRHa) during cancer treatment can preserve the fertility of young female cancer subjects. Approximately 300 women with newly diagnosed breast cancer and up to 200 women with newly diagnosed lymphoma, acute leukemias or sarcomas will be recruited before start of cancer treatment. The full summary is on the listing.
Where, as registered
No US site; Sweden (17).
RecruitingNCT06282588
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
Phase 2 and 3
Cancer Research Antwerp
About 493 people
Started Dec 13, 2023
In plain words A Phase 2 and 3 study of triptorelin in male participants 18 and older, run by Cancer Research Antwerp. It plans to enroll about 493 people at 9 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Prostate Cancer.
Histopathology-proven PCa
High-risk locally advanced disease is defined as any of the following factors: PSA > 20 ng/mL OR T-stage 3 or 4 OR Gleason score 8-10 OR cN1.
An Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1.
Willingness to undergo a PSMA PET/ CT with or without contrast.
16 more inclusion criteria and the exclusion criteria are on the listing.
This Investigator-initiated, Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) study will be conducted in subjects with high-risk localized or locally advanced prostate cancer (PCa). The study contains both a randomized Phase 3 treatment intensification study, as well as a treatment de-intensification non-randomized Phase 2 study. The aim of the THUNDER study is to improve the outcome of high-risk PCa by improved risk stratification. The full summary is on the listing.
Where, as registered
No US site; Belgium (9).
RecruitingNCT05019846
SRT Versus SRT+ADT in Prostate Cancer
Phase 3
Marco Lorenzo Bonu
About 310 people
Started Sep 30, 2021
In plain words A Phase 3 study of triptorelin in male participants 18 to 80, run by Marco Lorenzo Bonu. It plans to enroll about 310 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 to 80. Conditions: Prostate Cancer.
Histological confirmation of prostate acinar adenocarcinoma with a minimum of 10 biopsy cores taken
Prostate protocol MRI for local staging
Patients belonging to intermediate unfavorable group according to the D'Amico/NCCN risk group classification:
-Grade group 3 or/and
14 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Triptorelin Embonate; Bicalutamide 50 mg
Registered summary
To clarify the role of short-term Androgen deprivation therapy (ADT) in the context of intermediate unfavorable and a subclass of high-risk patients treated with prostate Stereotactic radiotherapy (SRT). In intermediate unfavorable risk group, when choosing standard external beam radiotherapy, short term ADT is superior in terms of biochemical disease free survival (bDFS) to EBRT alone. In high risk disease, results of the combination therapy are even more clear. Prostate SRT has been endorsed as option for primary radical treatment for prostate cancer. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
RecruitingNCT07254429
COMPASS - COpenhagen MenoPAuSe Study
Phase 2
Martin Blomberg Jensen
About 192 people
Started Oct 2, 2025
In plain words A Phase 2 study of triptorelin in female participants 40 to 65, run by Martin Blomberg Jensen. It plans to enroll about 192 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 40 to 65. Conditions: Menopausal Osteoporosis; Bone Markers.
Women >40 years and ≤65 at screening visit
A body mass index between 18-35
Confirmed menopause
Method 1
8 more inclusion criteria and the exclusion criteria are on the listing.
During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to bone Loss and other complications. Estrogen therapy can help, but some women avoid it due to the increased risk of blood clots and cancer. This project will investigate whether blocking LH could offer a safe alternative to alleviate symptoms and complications of menopause since it is known from previous research that high LH levels contribute to both bone deterioration and metabolic issues. The full summary is on the listing.
Where, as registered
No US site; Denmark (1).
RecruitingNCT04356664
Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis
Phase 2 and 3
Hopital Foch
About 180 people
Started Mar 18, 2021
In plain words A Phase 2 and 3 study of triptorelin in female participants 18 to 36, run by Hopital Foch. It plans to enroll about 180 people at 1 site, none in the US.
Women aged 18 to 36 years (women ≥18 years to <36 years) with endometriosis and / or adenomyosis
Having benefited from In vitro fertilisation /intracytoplasmic micro-injection with freeze all and for whom the frozen embryon transfer of a blastocyst is planned
A normal uterine cavity
An MRI showing endometriosis and / or adenomyosis during the inclusion visit
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
GnRH agonist
Registered summary
Women suffering from endometriosis and/or adenomyosis may also suffer from infertility. GnRH agonist injection could improve implantation and therefore increase the pregnancy rate in these patients. This study was designed to evaluate effects of the additional of GnRH agonist (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen Embryon Transfer as compared to oestrogens and progestins only.
Where, as registered
No US site; France (1).
RecruitingNCT06763926
Intranasal Nafarelin For Triggering Oocyte Maturation
Phase 4
Fundacion Dexeus
About 154 people
Started Oct 14, 2026
In plain words A Phase 4 study of triptorelin in female participants 18 to 40, run by Fundacion Dexeus. It plans to enroll about 154 people at 5 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 40. Conditions: Fertility Preservation.
Women undergoing fertility preservation cycles with oocyte cryopreservation
Undergoing a progesterone-primed ovarian stimulation cycle (PPOS) with any commercially available gonadotropin preparation(s)
BMI 18 - 30 kg/m2
The exclusion criteria are on the listing.
What it tests, as registered
Subcutaneous Triptorelin; Intranasal nafarelin
Registered summary
This is a non-inferiority randomised, controlled clinical trial comparing subcutaneous triptorelin to intranasal nafarelin for the final maturation of oocytes in women undergoing fertility preservation cycles with oocyte cryopreservation undergoing ovarian stimulation.
Where, as registered
No US site; Spain (5).
RecruitingNCT05557604
Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer
Phase 2
Regina Elena Cancer Institute
About 146 people
Started Feb 2, 2021
In plain words A Phase 2 study of triptorelin in male participants 18 to 90, run by Regina Elena Cancer Institute. It plans to enroll about 146 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 to 90. Conditions: Prostate Cancer.
Histologically proven prostate adenocarcinoma
IR or HR in the NCCN definition
N0M0 at staging with choline or (preferably) PSMA PET-CT;
ECOG performance status between 0 and 2;
The exclusion criteria are on the listing.
What it tests, as registered
Decapeptyl
Registered summary
This is a prospective, open, randomized phase II trial.
Where, as registered
No US site; Italy (3).
RecruitingNCT07816562
Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST)
Phase 3
Fundación para la Investigación del Hospital Clínico de Valencia
About 126 people
Started Sep 17, 2024
In plain words A Phase 3 study of triptorelin in female participants 18 to 42, run by Fundación para la Investigación del Hospital Clínico de Valencia. It plans to enroll about 126 people at 1 site, none in the US.
Women with low ovarian response classified within one of the groups defined by the POSEIDON criteria.
The exclusion criteria are on the listing.
What it tests, as registered
Human chorionic gonadotropin (hCG); Follitropin delta; Triptorelin
Registered summary
This study aims to compare different ovulation triggering strategies in women with low ovarian reserve undergoing fresh in vitro fertilization (IVF) cycles. Ovulation triggering is a key step in IVF treatment, as it determines final oocyte maturation prior to oocyte retrieval. Participants are randomly assigned to one of three ovulation trigger approaches: human chorionic gonadotropin (hCG) alone, follitropin delta combined with hCG, or dual trigger using a gonadotropin-releasing hormone (GnRH) agonist plus hCG. The full summary is on the listing.
Where, as registered
No US site; Spain (1).
RecruitingNCT06225284
Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients
Phase 2
National Taiwan University Hospital
About 124 people
Started Aug 22, 2024
In plain words A Phase 2 study of triptorelin in female participants 18 and older, run by National Taiwan University Hospital. It plans to enroll about 124 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Triple Negative Breast Cancer; Premenopausal Breast Cancer.
Written informed consent must be obtained before any assessment is performed.
Female patients aged ≥ 18 years at screening; Must be premenopausal according to serum E2, FSH level.
Histological confirmed TNBC, as defined by the most recent ASCO/CAP guidelines. Hormone receptor-low/HER2 negative as defined by ER 1% to <10% and/or PR 1% to <10% on IHC staining; neither hormone receptor may be ≥ 10%; and HER2-negative…
Have previously untreated locally advanced non-metastatic (M0) TNBC and hormone receptor-low/HER2-negative defined as the following combined primary tumor (T) and regional lymph node (N) staging per current AJCC staging criteria for breast…
14 more inclusion criteria and the exclusion criteria are on the listing.
Breast cancer (BC), especially premenopausal, is emerging rapidly in East Asia in recent 20 years. Half of the breast cancer patients in Asia are younger than 50 years of age. In general, younger or premenopausal patients are associated with poorer prognosis. Premenopausal patients have higher estrogen levels than those in older (postmenopausal) patients. Estrogen is known to suppress anti-tumor T cell response and leading to tumor progression in different animal models (Clin Cancer Res 2016 22:6204), including lung cancer, melanoma, ovarian cancer. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT07696351
Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis
Phase 4
Li-jun Ding
About 120 people
Started Aug 1, 2025
In plain words A Phase 4 study of triptorelin in female participants 18 to 39, run by Li-jun Ding. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 39. Conditions: Deep Infiltrating Endometriosis (DIE); Infertility.
Female patients aged 18 to 39 years.
Diagnosed with deep infiltrating endometriosis by ultrasound at the study center.
Undergoing the first frozen-thawed embryo transfer cycle with hormone replacement therapy for endometrial preparation.
Having at least one good-quality frozen embryo.
1 more inclusion criterion and the exclusion criteria are on the listing.
Deep infiltrating endometriosis is a severe form of endometriosis that may reduce fertility and negatively affect pregnancy outcomes after assisted reproductive treatment. Gonadotropin-releasing hormone agonist pretreatment may suppress endometriotic lesions, reduce inflammation, and improve endometrial receptivity, but its benefit before frozen-thawed embryo transfer remains uncertain. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07861399
Dual Trigger VS HCG Trigger for Final Oocyte Maturation in Normal Responders
No phase
Al-Azhar University
About 100 people
Started Sep 1, 2026
In plain words A study of triptorelin in female participants 20 to 40, run by Al-Azhar University. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 20 to 40. Conditions: ICSI; IVF; Normal Responders; Infertility Assisted Reproductive Technology; Infertile Women Undergoing IVF or ICSI; Infertile Women Undergoing ART; Triggering Ovulation; Oocyte Maturation.
Women aged 20-40 years.
Body mass index (BMI) between 18 and 30 kg/m².
Undergoing ICSI treatment using a GnRH antagonist protocol.
Normal ovarian reserve and expected normal ovarian response.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Dual trigger (human chorionic gonadotropin plus GnRH-agonist); hCG trigger
Registered summary
To compare the embryological and reproductive outcomes of dual trigger versus conventional hCG trigger for final oocyte maturation in normal responder patients undergoing ICSI cycles.
Where, as registered
No US site; Egypt (1).
RecruitingNCT05982093
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
Phase 2
SOLTI Breast Cancer Research Group
About 96 people
Started Feb 3, 2023
In plain words A Phase 2 study of triptorelin in female participants 35 and older, run by SOLTI Breast Cancer Research Group. It plans to enroll about 96 people at 15 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 35 and older. Conditions: Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Premenopausal Breast Cancer.
Signed informed consent must be obtained prior to any trial-specific procedure.
Female patients who are at least 35 years of age on the day of signing informed consent.
Patient is premenopausal at the time of study entry
Patient had last menstrual period within the last 6 months. OR
30 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Elacestrant; Triptorelin; Tamoxifen 20 mg
Registered summary
PREMIERE parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory window of opportunity study in premenopausal women with primary operable HR+/HER2-negative breast cancer with aiming at evaluating the biological effects of elacestrant with or without triptorelin.
Where, as registered
No US site; Spain (15).
RecruitingNCT05851547
Dose Escalation For INtraprostatic LEsions
Phase 2
Ottawa Hospital Research Institute
About 54 people
Started Nov 23, 2023
In plain words A Phase 2 study of triptorelin in male participants 18 and older, run by Ottawa Hospital Research Institute. It plans to enroll about 54 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Prostatic Neoplasms.
Histologically confirmed adenocarcinoma of the prostate
Unfavourable intermediate-risk or high-risk localized disease
Unfavourable intermediate-risk prostate cancer is defined as intermediate-risk prostate cancer \[that is, no high-risk features and one or more intermediate-risk factors: T2b-T2c, Gleason 3+4 (grade group 2) or Gleason 4+3 (grade group 3),…
High-risk localized prostate cancer is defined as at least one of the following: T3a-T3b; Gleason ≥ 8 (grade group 4 or grade group 5); PSA > 20 μg/L
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Prostate SBRT with Focal Boost; Triptorelin Injection
Registered summary
External beam radiotherapy combined with androgen deprivation therapy is a standard treatment option for localized prostate cancer. The current standard involves delivering radiotherapy uniformly throughout the prostate gland in daily fractions, five days per week, for approximately four weeks. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT06525155
Effect GnRH Agonist Administration in Endometriosis Cyst Patients
Phase 3
Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
About 32 people
Started Jan 2, 2024
In plain words A Phase 3 study of triptorelin in female participants 18 to 40, run by Rumah Sakit Pusat Angkatan Darat Gatot Soebroto. It plans to enroll about 32 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 40. Conditions: Endometriosis.
Female subjects aged 18 to 40 years.
The subjects was diagnosed with endometriosis cysts.
Willing to participate in research and sign informed consent before all research-related activities begin.
Regular menstruation (within 25 - 35 day intervals) in the last 3 months before the study was conducted.
The exclusion criteria are on the listing.
What it tests, as registered
Triptorelin Embonate; Triptorelin Embonate
Registered summary
Endometriosis is a chronic disease that affects 10-15% of women of childbearing age. The most common symptom is pelvic pain. One of the treatment options that has been proven effective in treating endometriosis symptoms, including endometriosis pain, is triptorelin. Triptorelin has also received a distribution permit in Indonesia for the treatment of endometriosis. However, patient compliance in using this drug is very low due to high medical costs and side effects of the drug. Standard treatment with triptorelin is generally given every 4 weeks. The full summary is on the listing.
Where, as registered
No US site; Indonesia (1).
Not yet recruitingNCT06487143
Efficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP
Phase 4
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
About 134 people
Starts Jul 1, 2024 (estimated)
In plain words A Phase 4 study of triptorelin in people 2 to 10, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. It plans to enroll about 134 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 2 to 10. Conditions: Central Precocious Puberty.
Early appearance of secondary sexual characteristics, specifically breast development in girls before 8 years old or menarche before 10 years old, and testicular enlargement in boys before 9 years old.
Gonadal enlargement: pelvic ultrasound shows that girls have at least one ovarian follicle with a diameter \>4mm, and breast development is at least at Tanner stage II; boys have a testicular volume ≥ 4 ml (measured with Prader…
GnRH stimulation test: LH peak value ≥ 5 IU/L (chemiluminescence method), with an LH peak/FSH peak ratio ≥ 0.6.
Bone age (BA) exceeds chronological age (CA) by 1 year or more (based on bone age assessment during the screening period at this center).
3 more inclusion criteria and the exclusion criteria are on the listing.
The primary objective of this study is to compare the efficacy of the 3-month formulation and 1-month formulation of triptorelin and to assess the short-term effects of the 3-month formulation of triptorelin on glucose and lipid metabolism, body composition, and bone density in Chinese ICPP patients.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07782840
QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy
Phase 2
Hebei Medical University Fourth Hospital
About 40 people
Starts Oct 1, 2026 (estimated)
In plain words A Phase 2 study of triptorelin in female participants 18 to 75, run by Hebei Medical University Fourth Hospital. It plans to enroll about 40 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 75. Conditions: Breast Cancer.
Female participants aged 18 to 75 years.
Histologically or pathologically confirmed HR-positive/HER2-negative early or locally advanced breast cancer, classified as stage IIB-IIIC, with a poor response to two cycles of neoadjuvant TAC chemotherapy.
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
No prior antitumor treatment other than the two cycles of neoadjuvant TAC chemotherapy specified in this study, including no prior immune checkpoint inhibitor therapy.
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Iparomlimab and Tuvonralimab (QL1706); Aromatase Inhibitor (AI); CDK4/6 inhibitor; Ovarian function suppression
Registered summary
This study will evaluate whether adding QL1706 (iparomlimab and tuvonralimab) to neoadjuvant endocrine therapy improves tumor response in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer who have had a poor response to neoadjuvant chemotherapy. The full summary is on the listing.